The 2012 Genitourinary Cancers Symposium, to be held Feb. 2-4, will feature potentially practice-changing data on two novel agents – MDV3100 and radium-223 chloride – in prostate cancer. * Results of the phase III AFFIRM trial, to be reported in full Feb. 2, show that the investigational oral androgen-receptor signaling inhibitor MDV3100 prolongs overall survival in progressive castration-resistant prostate cancer after failure of docetaxel (Taxotere).Men given this agent lived on average nearly...